Unlock instant, AI-driven research and patent intelligence for your innovation.

Substituted indoles and their use as integrin antagonists

a technology of indole and antagonist, which is applied in the field of substituted indole compounds, can solve the problems of increased mortality, incapacitation, and increased bone fractures

Inactive Publication Date: 2005-09-22
3 DIMENSIONAL PHARMA
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about new compounds called substituted indoles that can stop the growth and spread of tumors, as well as treat other diseases like osteoporosis and rheumatoid arthritis. These compounds can also prevent the growth of blood vessels that can cause restenosis. The invention also includes a process for making these compounds and a pharmaceutical composition containing them."

Problems solved by technology

When bone resorbing activity exceeds bone forming activity, the result is osteoporosis, a condition which leads to an increased number of bone fractures, incapacitation and increased mortality.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted indoles and their use as integrin antagonists
  • Substituted indoles and their use as integrin antagonists
  • Substituted indoles and their use as integrin antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

3-{5-[3-(2-Pyridylamino)propoxy]indolyl}propanoic acid ammonium salt

[0283]

a). 2-(3-Hydroxypropyl)aminopyridine N-oxide

[0284] A mixture of 2-chloropyridine-N-oxide hydrochloride (3.32 g, 20 mmol), 3-amino-1-propanol (3.06 mL, 40 mmol), NaHCO3 (8.4 g, 100 mmol) in tert-amyl alcohol (20 mL) was heated to reflux. After stirring overnight, the reaction mixture was cooled, diluted with methylene chloride (100 mL), and suction filtered to remove the insoluble materials. The filtrate was concentrated and reconcentrated from methylene chloride twice. The residue was recrystallized from ethyl acetate and hexane, collected by filtration, washed with ethyl acetate, and dried under high vacuum to give the title compound as a pale yellow solid (3.2 g, 95%). 1H-NMR (400 MHz, CDCl3) δ 8.07 (d, J=6.5 Hz, 1H), 7.32 (br s, 1H), 7.21 (t, J=8.6 Hz, 1H), 6.64 (d, J=8.5 Hz, 1H), 6.53 (t, J=6.7 Hz, 1H), 3.75 (t, J=5.8 Hz, 2H), 3.47 (q, J=6.2 Hz, 2H), 1.86 (t, J=6.0 Hz, 2H).

b). 2-(3-Hydroxypropyl)aminopy...

example 2

3-{5-[3-(2-Pyridylamino)propoxy]indolyl}acetic acid ammonium salt

[0290]

a). Methyl 2-(5-benzyloxyindolyl)acetate

[0291] 5-Benzyloxyindole (0.80 g, 3.58 mmol) was dissolved in anhydrous N,N-dimethylformamide (20 mL) and treated with 60% sodium hydride in mineral oil (0.36 g, 9.00 mmol) at ambient temperature. After 2 h, ethyl bromoacetate (0.45 mL, 4.06 mmol) was added, the reaction stirred for 6 h, and additional sodium hydride (0.36 g, 9.00 mmol) was added. The reaction stirred for 3 days, the N,N-dimethylformamide was removed in vacuo, and the residue was dissolved in methylene chloride. The resulting solution washed with 10% aqueous HCl, water, and brine, dried over anhydrous sodium sulfate, and filtered. The evaporated filtrate was then dissolved in N,N-dimethylformamide (20 mL) and treated with cesium carbonate (1.57 g, 4.80 mmol) and iodomethane (0.30 mL, 3.75 mmol) at ambient temperature for 18 h. The reaction was concentrated in vacuo, the crude product dissolved in methylen...

example 3

3-{2-Methyl-5-[3-(2-pyridylamino)propoxy]indolyl}propanoic acid sodium salt

[0295]

a). 3-(5-Methoxy-2-methylindolyl)propanoic acid

[0296] 5-Methoxy-2-methylindole (0.50 g, 3.10 mmol) was dissolved in anhydrous N,N-dimethylformamide (25 mL) and treated with 60% sodium hydride in mineral oil (0.19 g, 4.70 mmol) at ambient temperature for 2 h. Ethyl 3-bromopropionate (0.60 mL, 4.20 mmol) was added, the reaction stirred for 3.5 h, treated with additional sodium hydride (0.20 g, 4.88 mmol), and stirred another 24 h. After concentration in vacuo, the crude product was dissolved in methylene chloride, the solution washed with dilute aqueous HCl and brine, dried over anhydrous sodium sulfate, and filtered. The evaporated filtrate was purified by flash column chromatography (1:1 hexane:ethyl acetate as eluant) giving the title compound as a yellow-orange solid (0.56 g, 77%). 1H NMR (400 MHz, CDCl3): δ 7.16 (d, 1H, J=8.8 Hz), 7.00 (d, 1H, J=2.4 Hz), 6.80 (dd, 1H, J=8.8 Hz, 2.4 Hz), 6.17 (s, 1H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit, under 35 U.S.C. § 119(e), of the earlier filing dates of U.S. provisional application Ser. No. 60 / 264,260, filed Jan. 29, 2001, and U.S. provisional application Ser. No. 60 / 324,519, filed Sep. 26, 2001. The contents of both above-referenced provisional applications are fully incorporated by reference.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. [0004] 2. Related Art [0005] Integrins are cell surface glycoprotein receptors which bind extracellular matrix proteins and mediate cell-cell and cell-extracellular matrix interactions (generally referred to as cell adhesion events) (Hynes, R. O., Cell 69:11-25 (1992)). These receptors are composed of noncov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/404A61K31/4375A61K31/4439A61K31/4709A61K31/5383A61P3/06A61P3/10A61P7/06A61P9/00A61P9/10A61P19/10A61P25/00A61P25/04A61P25/08A61P25/18A61P25/22A61P27/02A61P29/00A61P35/00A61P43/00C07D209/08C07D213/74C07D401/12C07D401/14C07D403/12C07D471/04C07D498/04
CPCC07D209/08C07D213/74C07D401/12C07D471/14C07D471/02C07D471/04C07D401/14A61P19/00A61P19/10A61P25/00A61P25/04A61P25/08A61P25/18A61P25/22A61P27/00A61P27/02A61P29/00A61P35/00A61P3/06A61P43/00A61P7/06A61P9/00A61P9/10A61P3/10
Inventor LU, TIANBAOLAFRANCE, LOUIS V.TOMCZUK, BRUCE E.MARKOTAN, THOMAS P.MARUGAN SANCHEZ, JUAN J.MARDER, VICTOR J.U'PRICHARD, DAVID C.ANACLERIO, BETH M.GUO, ZIHONGPAN, WENZILEONARD, KRISTI A.
Owner 3 DIMENSIONAL PHARMA